scholarly journals Relations between coping skills, symptom severity, psychological symptoms, and quality of life in patients with irritable bowel syndrome

2019 ◽  
Vol 10 (1) ◽  
pp. 72 ◽  
Author(s):  
Farnaz Torkzadeh ◽  
Manizheh Danesh ◽  
Leila Mirbagher ◽  
Hamed Daghaghzadeh ◽  
MohammadHassan Emami
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Symptom Severity ◽  
Coping Skills ◽  
Psychological Symptoms ◽  
Irritable Bowel

scholarly journals Vitamin D status and quality of life in people with Irritable Bowel Syndrome

2020 ◽  
Vol 79 (OCE2) ◽  
Author(s):  
Claire Williams ◽  
Elizabeth Williams ◽  
Bernard Corde
Keyword(s):  
Quality Of Life ◽  
Vitamin D ◽  
Irritable Bowel Syndrome ◽  
Clinical Diagnosis ◽  
Symptom Severity ◽  
Serum Vitamin ◽  
Vitamin D Status ◽  
Baseline Serum ◽  
Irritable Bowel

AbstractIrritable Bowel Syndrome (IBS) is a chronic and debilitating functional disorder of the gastrointestinal tract with serious and detrimental impacts on quality of life. Its aetiology is largely unknown, and the identification of effective management strategies remains far from complete. Research suggests that people with IBS have a high prevalence of vitamin D deficiency, which may impact on symptom severity and quality of life.A double-blind, placebo-controlled, 2-arm, parallel-design study is underway to investigate the effect of a 12 week, 3,000IU vitamin D p.d. supplementation on symptom severity and quality of life in participants with a clinical diagnosis of IBS. This report assesses whether relationships exist between vitamin D status, IBS severity and quality of life in the baseline (cross-sectional) data.Eighty males and females with a clinical diagnosis of IBS were recruited in phase I of the trial in January-April 2018. Mixed-type IBS and constipation-predominant IBS were the more frequent subtypes (36% and 33%), while diarrhoea-predominant had a lower prevalence (23%). More females (n = 65) than males (n = 15) were recruited to the study which reflects the reported greater prevalence of IBS in women. Baseline serum 25(OH)D levels in participants were classified as deficient 23.1% (n = 18) (< 30nmol/L), insufficient 37.2% (n = 29) (31–49 nmol/L) and sufficient 39.7% (n = 31) (> 50 nmol/L) respectively. The sample median for serum vitamin D at baseline was 42.2 (± 28.3) nmol/L. Quality of Life was significantly associated with two IBS sub-symptoms: pain (p = 0.037, r = 0.233) and distension severity (p = 0.009, r = 0.291). Neither Quality of Life, nor IBS symptom severity score, correlated with vitamin D status in the sample.This study found no relationship between baseline vitamin D status and symptom severity or quality of life in this subsample. Two publications report vitamin D intervention improves quality of life in participants with IBS. It is possible that the unusual homogeneity of these studies enabled identification of these relationships.These initial observations agree with previous reports of widespread vitamin D insufficiency in people with IBS. Analysis of full trial outcomes (July 2019) will determine whether vitamin D supplementation is beneficial for either symptoms severity or quality of life in people with IBS.

scholarly journals Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome

2019 ◽  
Vol 31 (8) ◽  
Author(s):  
Zsa Zsa R. M. Weerts ◽  
Lisa Vork ◽  
Zlatan Mujagic ◽  
Daniel Keszthelyi ◽  
Martine A. M. Hesselink ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Symptom Severity ◽  
Irritable Bowel

Mo1616 Resilience Is Decreased in Irritable Bowel Syndrome (IBS) and Associated With Poorer Quality of Life and Greater Symptom Severity

2016 ◽  
Vol 150 (4) ◽  
pp. S731 ◽  
Author(s):  
Vien Nguyen ◽  
Wendy Shih ◽  
Angela Presson ◽  
Bruce D. Naliboff ◽  
Lisa A. Kilpatrick ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Symptom Severity ◽  
Irritable Bowel

scholarly journals The Association of Insomnia, Perceived Immune Functioning, and Irritable Bowel Syndrome Complaints

2018 ◽  
Vol 7 (9) ◽  
pp. 238 ◽  
Author(s):  
Stephanie Balikji ◽  
Marlou Mackus ◽  
Karel Brookhuis ◽  
Johan Garssen ◽  
Aletta Kraneveld ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Symptom Severity ◽  
General Health ◽  
Negative Impact ◽  
Sleep Onset ◽  
Sleep Onset Latency ◽  
Immune Functioning ◽  
Irritable Bowel

Background: Irritable bowel syndrome (IBS) can have a significant negative impact on quality of life, mood and wellbeing. The aim of this study was to investigate the association between experiencing IBS symptoms and insomnia, and perceived health status. Method: An online survey was conducted among n = 1950 Dutch university students (83.6% women). IBS was assessed with the Birmingham IBS Symptom Questionnaire, quality of life with the WHO-5 wellbeing index, and sleep outcomes with the SLEEP-50 questionnaire. Perceived immune functioning and general health were assessed using 1-item scales. Results: IBS symptom severity was significantly associated with insomnia complaints (r = 0.32, p = 0.0001), sleep quality (r = −0.21, p = 0.0001), sleep onset latency (r = 0.11, p = 0.0001) and the number of nightly awakenings (r = 0.24, p = 0.0001). Total sleep time was not significantly associated with IBS symptom severity. Significant correlations were also found between IBS symptom severity and perceived general health (r = −0.30, p = 0.0001), perceived immune functioning (r= −0.25, p = 0.0001), and quality of life (r = −0.24, p = 0.0001). Conclusions: Experiencing IBS complaints is associated with reduced perceived immune functioning, a poorer perception of general health, and sleep disturbances. These effects are reflected in a significantly lower reported quality of life in subjects with more IBS and/or sleep complaints.

Efficacy and safety of Achillea wilhelmsii C. Koch capsules on symptom severity and quality of life in patients with irritable bowel syndrome: a randomized, placebo-controlled clinical trial

2019 ◽  
Vol 16 (4) ◽  
Author(s):  
Padide Derakhshande ◽  
Seyed Jafar Navabi ◽  
Yalda Shokoohinia ◽  
Hojjat Rouhi-Broujeni ◽  
Fateme Deris ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Symptom Severity ◽  
Significant Difference ◽  
Before And After ◽  
The Mean ◽  
Achillea Wilhelmsii ◽  
Irritable Bowel

Abstract Background Irritable bowel syndrome (IBS) is one of the most common digestive diseases. The aim of this clinical trial was to determine the effectiveness of Achillea wilhelmsii C. Koch on the symptom severity and quality of life (QOL) in patients with IBS. Methods The patients were randomized into two groups of 45 each. The QOL and symptom severity of the patients were evaluated at baseline and at completion of the treatments by means of IBS-QOL and IBS severity index. Results The mean severity of clinical symptoms in the Achillea wilhelmsii C. Koch receiving groups before and after the treatment was 282.56 ± 103.57 and 178.06 ± 88.40, and in the placebo group was 265.93 ± 93.56 and 197.74 ± 106.26, respectively. The mean QOL in the Achillea wilhelmsii C. Koch receiving group before and after treatment was 51.49 ± 11.98 and 50.44 ± 13.39 and in the placebo group was 60.71 ± 11.97 and 58.39 ± 11.67, respectively. In both groups, there was a significant difference in the recovery rate in each group (p<0.05). However, the mean difference between the two groups before and after intervention was not significantly different (p>0.05). Also, no patient reported any adverse events during the trial. Although the symptom severity and QOL in both groups were improved compared to those before intervention, there was no significant difference between the two groups. Conclusion It is recommended to conduct future studies with larger sample size and longer treatment periods, and also investigate the efficacy on the IBS subtypes, separately.

Sign in / Sign up

Export Citation Format

Share Document